RxDoctor Payments Data

van Woeltz, MD

Neurology · Paducah, KYNPI 1447269451

Payments from drug & device makers

$7,311in general payments, 2019–2025

Across 473 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • EMD Serono, Inc.$599
  • Supernus Pharmaceuticals, Inc.$598
  • Amgen$494
  • AstraZeneca$321
  • Teva Pharmaceuticals USA, Inc.$284
  • plus $3K from 38 others

What the payments were for

  • Speaking & faculty fees$721%
  • Food & beverage$6,98095%
  • Education$2594%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,311 in reported general payments places this provider in the 60th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$184,581
Medicare patients
535
Services billed
1,947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$108,736
MayzentSiponimod11$106,498
AptiomEslicarbazepine Acetate24$59,334
QuliptaAtogepant31$33,797
EliquisApixaban49$28,766
VimpatLacosamide13$22,097
NuedextaDextromethorphan Hbr/Quinidine13$19,593
RytaryCarbidopa/Levodopa15$19,288
Emgality PenGalcanezumab-Gnlm20$17,587
Oxtellar XrOxcarbazepine19$14,618
Ajovy SyringeFremanezumab-Vfrm18$12,957
Dalfampridine ErDalfampridine19$8,710
Oxcarbazepine124$6,293
Rivastigmine27$6,025
Memantine Hcl316$5,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$150$108,73613 claims
NovartisMayzent$261$106,49811 claims
Sunovion Pharmaceuticals Inc.Aptiom$168$59,33424 claims
AbbVieQulipta$1,846$33,79731 claims
PfizerEliquis$165$28,76649 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$29$27,222116 claims
UCB, Inc.Vimpat$28$22,09713 claims
Avanir Pharmaceuticals, Inc.Nuedexta$185$19,59313 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$598$14,61819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 210 neurology providers in Kentucky.

Other neurology in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →